Key Learnings from Women Founders In Switzerland
Below are videos of three women entrepreneurs being interviewed by Jim Pulcrano, Professor at IMD
Related Articles
Clinical Oncology Bridges Gaps Between Medical Oncology, Radiation Oncology, and Clinical Research: With D. Ross Camidge, MD, PhD; and Duncan McLaren, MBBS, BSc, FRCR, FRCP
Drs Camidge and McLaren discuss Dr McLaren’s journey to medical school and his experience as a clinical oncologist with expertise across disciplines.
Lactylation in cancer: Current understanding and challenges
Lactylation, a recently identified post-translational modification, has initially been linked to gene transcription regulation through epigenetic mechanisms. However, its role in tumorigenesis—whether as a major…
Toripalimab Plus Chemo: A First-Line Option for ES-SCLC?
Study authors said toripalimab plus chemotherapy could be a first-line treatment option, but authors of a related commentary said a global study may be needed…
FDA Approval Sought for Dato-DXd in EGFR-Mutated NSCLC
A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from multiple TROPION trials, following FDA feedback.
Low-Risk Individuals Should Not Currently Be Screened for… : Oncology Times
An abstract is unavailable.
SBRT Is Feasible for Localized Prostate Cancer
Five-fraction SBRT was noninferior to radiotherapy in a phase 3 trial of patients with low- to intermediate-risk localized prostate cancer.
AE Profiles and Dosing Schedules Define the Role of CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer
Kari Wisinski, MD, discusses factors that influence her decision between CDK4/6 inhibitors for patients with treatment-naive, HR+ metastatic breast cancer.
Dr Weiss on the Role of Breast Imaging in Breast Cancer Treatment Decision-Making
Anna Weiss, MD, discusses the significance of various imaging modalities in patients with breast cancer.
Dr Herbst on the Evolution of EGFR Inhibition in Lung Cancer
Roy S. Herbst, MD, PhD, discusses advances in EGFR inhibition throughout the past several decades in patients with lung cancer.
Btk inhibition: the importance of being selective
First generation Bruton’s tyrosine kinase (Btk) inhibitors were associated with both decreased thrombosis and increased bleeding. However, newer more selec
